COPD_A_215859 2959..2970

1Department of Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey; 2AstraZeneca, Dubai, United Arab Emirates; 3King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia; 4Clinic of Chest Diseases, Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey; 5Department of Chest Diseases, Ege University Faculty of Medicine, Izmir, Turkey; 6Department of Medicine, Faculty of Medicine, Kuwait University, Jabriya, Kuwait; 7AstraZeneca, Luton, UK; 8Kasr El Aini Faculty of Medicine, Cairo University, Cairo, Egypt; 9University of Cape Town Lung Institute, Department of Medicine and Division of Pulmonology, Groote Schuur Hospital, Cape Town, South Africa; 10Department of Pulmonology, University Hospital Issad Hassani, Béni Messous, Alger, Algeria; 11Respiratory Medicine Division, Zayed Military Hospital, Abu Dhabi, UAE Purpose: This study was performed to assess symptom variability and its impact on morning activities in stable patients with severe COPD in the Middle East and Africa (MEA) countries. Patients and methods: Non-interventional, cross-sectional study (NCT03425760) in patients with severe COPD (GOLD 2015, C, or D categories). Symptom variability was assessed directly by interviewing the patient and using the Global Chest Symptoms Questionnaire (GCSQ). The impact on morning activities was assessed using the Capacity of Daily Living during the Morning (CDLM) and the Morning Activities and Symptoms Questionnaire (MASQ). Results: A total of 3253 patients (mean±SD age: 64.1±9.5 years, 90.3% males) were enrolled. Overall, 81.6% and 83.4% of patients reported weekly and daily symptom variability, respectively. The number of exacerbations in the previous year, smoking cessation, and COPD GOLD D were the most consistent factors associated with symptom variability. The GCSQ score was significantly higher (p<0.001) in GOLD D than in GOLD C patients at each time during the day. In GOLD D, the mean (±SD) GCSQ score was higher at night (1.6±1.2, p<0.001) and in the morning (1.5±1.0, p<0.001) than in the afternoon (1.3±0.9), suggesting daytime variability of breathlessness and chest tightness. Overall, 60.0% of GOLD D patients (versus 13.6% GOLD C, p<0.0001) had difficulty getting out of bed due to COPD. Patients with symptom variability had significantly more difficulty to get out of bed, especially patients with chest tightness variability (p<0.0001) and wheezing variability (p<0.0001). The CDLM global score was significantly lower (p<0.0001) in GOLD D than in GOLD C patients (3.5±1.1 and 4.6 ± 3.5, respectively). Daily variability in chest tightness and wheezing was also significantly associated with CDLM scores (p<0.0001). Conclusion: In MEA countries, patients with severe stable COPD reported significant daily and weekly symptom variability which affects morning activities, particularly in GOLD D patients.

[1]  Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire , 2018, International journal of chronic obstructive pulmonary disease.

[2]  Kun Li,et al.  Daily Symptom Variability in Patients With Stable COPD: A Narrative Review , 2018, Western journal of nursing research.

[3]  L. Tariq,et al.  Adherence to COPD treatment in Turkey and Saudi Arabia: results of the ADCARE study , 2018, International journal of chronic obstructive pulmonary disease.

[4]  M. Miravitlles,et al.  Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial , 2017, International journal of chronic obstructive pulmonary disease.

[5]  T. Greulich,et al.  Prevalence of comorbidities in COPD patients by disease severity in a German population. , 2017, Respiratory medicine.

[6]  M. Miravitlles,et al.  Understanding the impact of symptoms on the burden of COPD , 2017, Respiratory Research.

[7]  N. Scichilone,et al.  Symptom variability and control in COPD: Advantages of dual bronchodilation therapy. , 2017, Respiratory medicine.

[8]  N. Chavannes,et al.  Morning symptoms in COPD: a treatable yet often overlooked factor , 2017, Expert review of respiratory medicine.

[9]  J. Cardoso,et al.  Understanding COPD: A vision on phenotypes, comorbidities and treatment approach. , 2016, Revista portuguesa de pneumologia.

[10]  A. McIvor,et al.  GOLD Stage and Treatment in COPD: A 500 Patient Point Prevalence Study. , 2016, Chronic obstructive pulmonary diseases.

[11]  U. Yılmaz,et al.  Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study , 2015, International journal of chronic obstructive pulmonary disease.

[12]  Anand A. Dalal,et al.  Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity , 2015, International journal of chronic obstructive pulmonary disease.

[13]  M. Çakır,et al.  Do females behave differently in COPD exacerbation? , 2015, International journal of chronic obstructive pulmonary disease.

[14]  D. Price,et al.  Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease , 2015, International journal of chronic obstructive pulmonary disease.

[15]  J. Croft,et al.  Smoking Prevalence and Cessation Characteristics among U.S. Adults With and Without COPD: Findings from the 2011 Behavioral Risk Factor Surveillance System , 2014, COPD.

[16]  D. Price,et al.  Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study , 2014, Respiratory Research.

[17]  N. Chavannes,et al.  COPD symptoms in the morning: impact, evaluation and management , 2013, Respiratory Research.

[18]  J. López-Campos,et al.  Symptom variability in COPD: a narrative review , 2013, International journal of chronic obstructive pulmonary disease.

[19]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[20]  D. Hyun,et al.  Patient's Perception of Symptoms Related to Morning Activity in Chronic Obstructive Pulmonary Disease: The SYMBOL Study , 2012, The Korean journal of internal medicine.

[21]  Dirkje S Postma,et al.  Prediction and course of symptoms and lung function around an exacerbation in chronic obstructive pulmonary disease , 2012, Respiratory Research.

[22]  M Cazzola,et al.  Symptom variability in patients with severe COPD: a pan-European cross-sectional study , 2010, European Respiratory Journal.

[23]  T. Welte,et al.  Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD , 2009, European Respiratory Journal.

[24]  M. Decramer,et al.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.

[25]  J A Anderson,et al.  Adherence to inhaled therapy, mortality and hospital admission in COPD , 2009, Thorax.

[26]  M. Partridge,et al.  Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey , 2009, Current medical research and opinion.

[27]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[28]  J. Wedzicha,et al.  COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.